On 7 September 2026, Hang Seng Indexes Company Limited recently announced the results of its 2026 sustainability ratings for listed companies, with the related index adjustments taking effect today. Fosun International Limited (HKEX stock code: 00656, “Fosun International”, “Fosun” or the “Group”), in recognition of its continued commitment and outstanding performance in sustainable development, has had its Hang Seng Sustainability Rating upgraded from AA- to AA+, marking a record high. The Group was also selected as a constituent of the Hang Seng Corporate Sustainability Benchmark Index for the seventh consecutive year and included as a constituent of the Hang Seng ESG 50 Index. After three consecutive years at the AA level, this latest upgrade underscores strong market and regulatory recognition of Fosun International’s long-standing practices and continued progress in environmental, social, and governance (“ESG”) performance.

HONG KONG, Aug. 28 — According to an announcement published by Fosun International Limited, ClubMed Lifestyle Group, a subsidiary of Fosun International Limited, has submitted a listing application to the Hong Kong Stock Exchange for its proposed separate listing on the Main Board. The joint sponsors are BNP Paribas, HSBC and J.P. Morgan, in alphabetical order.

On the morning of 28 August, Fosun International held its 2026 interim results presentation in Hong Kong. This marks Fosun’s return to Hong Kong to hold a results presentation for the first time in six years. The results presentation was attended by Guo Guangchang, Chairman of Fosun International; Wang Qunbin, Co-Chairman of Fosun International; Chen Qiyu, Co-CEO of Fosun International; Xu Xiaoliang, Co-CEO of Fosun International; and Gong Ping, CFO of Fosun International, together with a number of investors, analysts, and media representatives.

(Hong Kong, Shanghai, 27 August 2026) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its interim results for the six months ended 30 June 2026 (the “Reporting Period”).

(6 Aug. 2026) Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable development and corporate social responsibility (CSR), as well as its growing global brand influence.

On 29th July, Fosun International (00656.HK) issued a positive profit alert. Its profit attributable to owners of the parent for the first half of 2026 is expected to range from approximately RMB1.5 billion to RMB1.8 billion representing an increase of approximately 127% to 172% compared to the same period last year. The board of directors (the “Board”) considers that such increase is mainly attributable to the strong resilience demonstrated by its core industries in the first half of 2026, the steady improvement in operational quality, and the significant increase in industrial operation profit compared to the same period last year.

On 30 June 2026, Corporate Governance Asia presented the 16th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International Limited (“Fosun International”, “Fosun” or the “Group”) (HKEX stock code: 00656) were both honored with Asia’s Best CEO. In addition, Fosun International received Sustainable Asia Award 2026, Best Environmental Responsibility Award and Best Corporate Communications Award.

The most authoritative corporate governance magazine in the Asia Pacific region, Corporate Governance Asia, has recently presented the 16th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International, were awarded Asia’s Best CEO by the magazine.

Shanghai, June 9, 2026 — Henlius (2696.HK) announced that the New Drug Application (NDA) for a new indication of its self-developed anti-PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab, trade name in Europe: Hetronifly^®) , in combination with Oxaliplatin and S-1 for neoadjuvant treatment of resectable gastric cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy after surgery, has been officially approved by the China National Medical Products Administration (NMPA) under the priority review pathway.